this clinical research study. 
5. POTENTIAL BENEFITS: The use of the marked cells to identify 
the sources of relapse may be of benefit to patients on 
future protocols but this research will not be of immediate 
benefit to patients currently entering this trial. The 
major benefit is to patients in the future who are 
participating in this study. The evaluation of the 
contribution of the peripheral blood versus the bone marrow 
will help in the design of the bone marrow and peripheral 
blood. 
6. ALTERNATE PROCEDURES OR TREATMENTS: Participation in this 
marking study is totally optional and the treatment on 
autologous transplant protocols may be carried out whether 
or not patients participate in the marking study. The 
patient may decline to have marking but still have the bone 
marrow or peripheral blood transplant of his or her own 
cells . 
UNDERSTANDING OF PARTICIPANTS 
7. I have been given an opportunity to ask any questions 
concerning the investigational regimen involved and the 
investigator has willingly replied to my inquiries. This 
investigational treatment program will be administered under 
the above numbered, titled and described clinical research 
protocol at this institution. I hereby authorize Dr. 
, the attending physician/ investigator and 
designated associates to administer this investigational 
treatment program. 
8. I have been told and understand that my participation is 
voluntary. I may decide not to participate, or withdraw my 
consent and discontinue my participation at any time. Such 
action will be without prejudice and there shall be no 
penalty or loss of benefits to which I may otherwise be 
entitled, and I will continue to receive treatment by my 
physician at this institution. 
Should I decide not to participate or withdraw my consent 
from participation in this clinical research, I have been 
advised that I should discuss the consequences or effects of 
my decision with my physician. 
In addition, I understand that the investigator may 
discontinue the clinical research study if, in the sole 
opinion and discretion of the investigator, the study or 
treatment offers me little or no future benefit, or the 
supply of medication ceases to be available or other causes 
prevent continuation of the clinical research study. The 
investigator will notify me should such circumstances arise 
and my physician will advise me about available treatment 
which may be of benefit at that time. 
Recombinant DNA Research, Volume 16 
[407] 
